Why did Novo Nordisk pull its paperwork to expand the use of Wegovy for a common type of heart failure? How will we know if the the government gets a good deal in the first round of drug pricing negotiations? And has Allison thought about anything other than venture capital for the last couple of months?
We discuss all that and more on this week’s episode of “The Readout LOUD.” STAT’s Washington Correspondent John Wilkerson joins us to discuss the first round of drug pricing negotiations under the Inflation Reduction Act, which will wrap up by September 1. We also cover the latest news in the life sciences including the merger of AI drug development companies Recursion Pharmaceuticals and Exscientia, Novo Nordisk’s decision to pause its regulatory submission for Wegovy’s use in patients with heart failure with preserved ejection fraction, and the state of biotech VC.
For more on how experts view the drug pricing negotiations, go here; for details on the Recursion-Exscientia deal, go here; for more Novo Nordisk’s Wegovy decision, go here; for more details on why VCs are pacing for another record-low fundraising year, go here; and to purchase STAT’s fifth annual “Ranking Biotech’s Top Venture Capital Firms” report, go here.
Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.
To submit a correction request, please visit our Contact Us page.
